Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives

QR Code

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives

Â© 2017 Catapano et al. Heterozygous familial hypercholesterolemia (FH) is a genetic disorder characterized by high low-density lipoprotein cholesterol levels from birth, which exposes the arteries to high levels of atherogenic lipoproteins lifelong and results in a significantly increased risk of p...

Full description

Bibliographic Details
Main Authors:	Catapano, A., Pirillo, A., Norata, Giuseppe
Format:	Journal Article
Published:	2017
Online Access:	http://hdl.handle.net/20.500.11937/63283

Similar Items

Targeting PCSK9 for hypercholesterolemia
by: Norata, Giuseppe, et al.
Published: (2014)

PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
by: Norata, Giuseppe, et al.
Published: (2014)

PCSK9 inhibition in statin-intolerant HeFH patients: What's new?
by: Casula, M., et al.
Published: (2017)

PCSK9 inhibitors and dyslipidemia: The clinical evidence
by: Norata, Giuseppe
Published: (2014)

Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia
by: Grigore, L., et al.
Published: (2013)

Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
by: Tibolla, G., et al.
Published: (2011)

New therapeutic principles for familial hypercholesterolemia
by: Norata, Giuseppe
Published: (2014)

Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps
by: Baragetti, A., et al.
Published: (2018)

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans
by: Baragetti, A., et al.
Published: (2017)

Squaring up the health economics of PCSK9 monoclonal antibodies ‘down under’
by: Watts, G., et al.
Published: (2018)

Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering
by: Norata, Giuseppe, et al.
Published: (2016)

Patients’ Perceptions and Experiences of Familial Hypercholesterolemia, Cascade Genetic Screening and Treatment
by: Hardcastle, Sarah, et al.
Published: (2015)

Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia
by: Hagger, Martin, et al.
Published: (2018)

High-density lipoprotein subfractions - What the clinicians need to know
by: Pirillo, A., et al.
Published: (2013)

Postprandial lipemia as a cardiometabolic risk factor
by: Pirillo, A., et al.
Published: (2014)

Vascular inflammation and low-density lipoproteins: Is cholesterol the link? A lesson from the clinical trials
by: Catapano, A., et al.
Published: (2017)

Therapy and clinical trials: Aggressive statin therapy versus combined and emerging approaches
by: Catapano, A., et al.
Published: (2011)

Niemann-pick C1-like 1 (NPC1L1) inhibition and cardiovascular diseases
by: Pirillo, A., et al.
Published: (2016)

LOX-1, OxLDL, and atherosclerosis
by: Pirillo, A., et al.
Published: (2013)

HDLs, immunity, and atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2011)

Treating high density lipoprotein cholesterol (HDL-C): Quantity versus quality
by: Pirillo, A., et al.
Published: (2013)

HDL in infectious diseases and sepsis
by: Pirillo, A., et al.
Published: (2015)

Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?
by: Catapano, A., et al.
Published: (2017)

Strategies for the use of nonstatin therapies
by: Pirillo, A., et al.
Published: (2017)

Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease
by: de Gonzalo-Calvo, D., et al.
Published: (2017)

Apolipoprotein C-III: From Pathophysiology to Pharmacology
by: Norata, Giuseppe, et al.
Published: (2015)

Challenges in the health economics of familial hypercholesterolemia
by: Norman, Richard, et al.
Published: (2016)

Communicating Familial Hypercholesterolemia Genetic Information Within Families
by: Maxwell, Susannah, et al.
Published: (2009)

The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis
by: Pirillo, A., et al.
Published: (2018)

Emerging role of high density lipoproteins as a player in the immune system
by: Norata, Giuseppe, et al.
Published: (2012)

HDL: To treat or not to treat?
by: Pirillo, A., et al.
Published: (2014)

HDL in innate and adaptive immunity
by: Catapano, A., et al.
Published: (2014)

Novel protein biomarkers associated with coronary artery disease in statin-treated patients with familial hypercholesterolemia
by: Bos, S., et al.
Published: (2017)

In vivo and in vitro effects of phaleria macrocarpa (scheff.) boerl on low density lipoprotein and pcsk9 expression
by: Chong, Soo Ching
Published: (2011)

PCSK9 inhibitory activity of marine-derived compounds, aaptaminoids, and benzamide originated from Aaptos aaptos and Acanthaster planci as a potential treatment for atherosclerosis.
by: Habsah, Mohamad, et al.
Published: (2020)

Health literacy in familial hypercholesterolemia: A cross-national study
by: Hagger, Martin, et al.
Published: (2018)

HEALTH LITERACY IN FAMILIAL HYPERCHOLESTEROLEMIA: A CROSS-NATIONAL STUDY
by: Hagger, Martin, et al.
Published: (2018)

Phaleria macrocarpa (Scheff.) Boerl fruit aqueous extract enhances LDL receptor and PCSK9 expression in vivo and in vitro.
by: Chong, Soo Ching, et al.
Published: (2011)

Novel compound for use as medicament for treatment of hypercholesterolemia and atherosclerosis
by: Abd. Shukor, Mohd. Yunus, et al.
Published: (2014)

Amaranthus viridis L. as alternative treatment for hypercholesterolemia and atherosclerosis
by: Salvamani, Shamala
Published: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nov6m8sm33s8h84nknnp45pr9b